Multiyear Recurrent Pericarditis Disease Duration: Clinical Outcomes After Cessation of Long‐Term Interleukin‐1 Pathway Inhibition Provide Insights for Chronic Management
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.125.044021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Lucia Trotta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine Ospedale Fatebenefratelli Milan Italy. Hauptthemen laut MEDLINE: Pericarditis, Recombinant Fusion Proteins, Interleukin-1, Interleukin-1beta. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
Recurrent pericarditis is an interleukin‐1–mediated chronic autoinflammatory disease. The phase 3 study RHAPSODY (Rilonacept Inhibition of IL‐1 Alpha and IL‐1 Beta for Recurrent Pericarditis: a Pivotal Symptomatology and Outcomes Study; NCT03737110) and long‐term extension demonstrated that rilonacept reduced the risk of recurrence. After 3 years of rilonacept treatment in RHAPSODY, Italian patients returned to standard management, as rilonacept was not commercially available.
Methods
Clinical records from Italian RHAPSODY patients were retrospectively reviewed for the 18‐month period post–long‐term extension completion to assess recurrent pericarditis disease persistence and time to recurrence after rilonacept cessation/washout. The primary outcome was pericarditis recurrence (ie, pericarditis pain plus C‐reactive protein elevation). Safety was also assessed.
Results
Seventeen patients were included in this analysis. The median disease duration (from incident episode to long‐term extension completion) was 48 (interquartile range, 41–56) months; the median duration of continuous rilonacept treatment was 28 (interquartile range, 27–30) months. Fourteen (82%) of 17 patients experienced a post‐trial off‐treatment recurrence; the remaining patients (n=3) had no pericarditis recurrences and remained offtreatment. The median time to recurrence (n=14) was 8.0 (interquartile range, 6.0–9.0 weeks). Most patients’ (n=8) post‐trial off‐treatment recurrences were managed with interleukin‐1 pathway inhibition. Some (n=4) were managed with glucocorticoids, and few (n=2) were managed with NSAIDs/colchicine. No serious adverse events were experienced.
Conclusions
The vast majority (86%) of the patients who experienced an off‐treatment recurrence after 28 months of rilonacept restarted interleukin‐1 pathway inhibition or corticosteroids, suggesting that NSAIDs/colchicine are insufficient in the management of patients with prolonged advanced disease. Rilonacept cessation and subsequent passive gradual washout is an evidence‐based pragmatic approach to determine if continued therapy is warranted to prevent subsequent recurrences.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine Ospedale Fatebenefratelli Milan Italy.
- Department of Medicine University of Udine and Cardiothoracic Department, University Hospital Santa Maria della Misericordia Udine Italy.
- Advanced Cardiovascular Echocardiography Unit, Cardiovascular and Thoracic Department Città della Salute e della Scienza di Torino University Hospital Turin Italy.
- Division of Cardiology, Città della Salute e della Scienza di Torino University Hospital, Department of Medical Sciences University of Torino Turin Italy.
- Division of of Rheumatology Ospedale Pediatrico Bambino Gesù IRCCS [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center] Rome Italy.
- Kiniksa Pharmaceuticals Lexington MA USA.
ORCID-Profile: Lucia Trotta, Massimo Imazio, Emanuele Bizzi, Alessandro Andreis, Antonella Insalaco, JoAnn Clair, Allan L Klein, Enrico Tombetti, Antonio Brucato, John F Paolini
Zitieren
APA
Trotta, L., Imazio, M., Bizzi, E., Pancrazi, M., Andreis, A., Insalaco, A., Wang, S., Clair, J., Klein, A. L., Tombetti, E., Brucato, A., Paolini, J. F., & RHAPSODY Investigators (2026). Multiyear Recurrent Pericarditis Disease Duration: Clinical Outcomes After Cessation of Long‐Term Interleukin‐1 Pathway Inhibition Provide Insights for Chronic Management. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.044021
Vancouver
Trotta L, Imazio M, Bizzi E, Pancrazi M, Andreis A, Insalaco A, et al. Multiyear Recurrent Pericarditis Disease Duration: Clinical Outcomes After Cessation of Long‐Term Interleukin‐1 Pathway Inhibition Provide Insights for Chronic Management. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.044021
BibTeX
@article{Trotta2026,
author = {Trotta, Lucia and Imazio, Massimo and Bizzi, Emanuele and Pancrazi, Massimo and Andreis, Alessandro and Insalaco, Antonella and Wang, Sheldon and Clair, JoAnn and Klein, Allan L and Tombetti, Enrico and Brucato, Antonio and Paolini, John F and RHAPSODY Investigators, RHAPSODY Investigators},
title = {Multiyear Recurrent Pericarditis Disease Duration: Clinical Outcomes After Cessation of Long‐Term Interleukin‐1 Pathway Inhibition Provide Insights for Chronic Management},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.044021}
}
EUVIMED